CINQAIR® (reslizumab) Injection – About Asthma Control
Reslizumab Overview - Creative Biolabs
Teva files MAA for asthma treatment reslizumab
Dosing and Administration
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
FDA approves Teva's Cinqair (reslizumab) Injection
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Brand name: Auvi-Q
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Teva Announces Biologics License Application FDA Acceptance of Reslizumab For Asthma
Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Medication Detail
Reslizumab
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Attachment: Product Information: Reslizumab
TA479 Review decision paper
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
Reslizumab | New Drug Approvals
